Avecho Biotechnology Limited (AVEFF)
USD 0.0
(157.14%)
USD 0.0
(157.14%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 7.31 Million AUD | 118.78% |
| 2022 | 3.34 Million AUD | -36.23% |
| 2021 | 5.24 Million AUD | 56.38% |
| 2020 | 3.35 Million AUD | -36.89% |
| 2019 | 5.31 Million AUD | 10.69% |
| 2018 | 4.8 Million AUD | -41.72% |
| 2017 | 8.23 Million AUD | -38.3% |
| 2016 | 13.35 Million AUD | -56.56% |
| 2015 | 30.74 Million AUD | -39.6% |
| 2014 | 50.9 Million AUD | 18.49% |
| 2013 | 42.95 Million AUD | -33.0% |
| 2012 | 64.12 Million AUD | -16.27% |
| 2011 | 76.57 Million AUD | 42.42% |
| 2010 | 53.76 Million AUD | -20.18% |
| 2009 | 67.36 Million AUD | -2.64% |
| 2008 | 69.18 Million AUD | -59.66% |
| 2007 | 171.52 Million AUD | -1.14% |
| 2006 | 173.49 Million AUD | 1.42% |
| 2005 | 171.07 Million AUD | 50.02% |
| 2004 | 114.03 Million AUD | 287.76% |
| 2003 | 29.4 Million AUD | 98.19% |
| 2002 | 14.83 Million AUD | -19.34% |
| 2001 | 18.39 Million AUD | -11.81% |
| 2000 | 20.85 Million AUD | 309.32% |
| 1999 | 5.09 Million AUD | 214.49% |
| 1998 | 1.62 Million AUD | -70.66% |
| 1997 | 5.52 Million AUD | -83.27% |
| 1996 | 33.01 Million AUD | -4.27% |
| 1995 | 34.48 Million AUD | 208.07% |
| 1994 | 11.19 Million AUD | -5.74% |
| 1993 | 11.87 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 5.86 Million AUD | -19.88% |
| 2024 Q2 | 5.86 Million AUD | 0.0% |
| 2023 Q3 | 7.31 Million AUD | 86.62% |
| 2023 Q4 | 7.31 Million AUD | 0.0% |
| 2023 Q1 | 3.92 Million AUD | 17.23% |
| 2023 FY | 7.31 Million AUD | 118.78% |
| 2023 Q2 | 3.92 Million AUD | 0.0% |
| 2022 Q4 | 3.34 Million AUD | 0.0% |
| 2022 FY | 3.34 Million AUD | -36.23% |
| 2022 Q1 | 4.47 Million AUD | -14.7% |
| 2022 Q2 | 4.47 Million AUD | 0.0% |
| 2022 Q3 | 3.34 Million AUD | -25.24% |
| 2021 Q3 | 5.24 Million AUD | -20.56% |
| 2021 Q4 | 5.24 Million AUD | 0.0% |
| 2021 Q2 | 6.6 Million AUD | 0.0% |
| 2021 FY | 5.24 Million AUD | 56.38% |
| 2021 Q1 | 6.6 Million AUD | 96.85% |
| 2020 FY | 3.35 Million AUD | -36.89% |
| 2020 Q1 | 4.5 Million AUD | -15.16% |
| 2020 Q2 | 4.5 Million AUD | 0.0% |
| 2020 Q3 | 3.35 Million AUD | -25.61% |
| 2020 Q4 | 3.35 Million AUD | 0.0% |
| 2019 Q2 | 6.89 Million AUD | 0.0% |
| 2019 FY | 5.31 Million AUD | 10.69% |
| 2019 Q1 | 6.89 Million AUD | 43.55% |
| 2019 Q4 | 5.31 Million AUD | 0.0% |
| 2019 Q3 | 5.31 Million AUD | -22.89% |
| 2018 Q2 | 6.81 Million AUD | 0.0% |
| 2018 Q3 | 4.8 Million AUD | -29.52% |
| 2018 FY | 4.8 Million AUD | -41.72% |
| 2018 Q1 | 6.81 Million AUD | -17.31% |
| 2018 Q4 | 4.8 Million AUD | 0.0% |
| 2017 Q4 | 8.23 Million AUD | 0.0% |
| 2017 Q3 | 8.23 Million AUD | -8.86% |
| 2017 Q2 | 9.04 Million AUD | 0.0% |
| 2017 FY | 8.23 Million AUD | -38.3% |
| 2017 Q1 | 9.04 Million AUD | -32.3% |
| 2016 FY | 13.35 Million AUD | -56.56% |
| 2016 Q2 | 25.22 Million AUD | 0.0% |
| 2016 Q1 | 25.22 Million AUD | -17.97% |
| 2016 Q4 | 13.35 Million AUD | -0.0% |
| 2016 Q3 | 13.35 Million AUD | -47.05% |
| 2015 Q4 | 30.74 Million AUD | 0.0% |
| 2015 Q2 | 36.78 Million AUD | 0.0% |
| 2015 Q3 | 30.74 Million AUD | -16.42% |
| 2015 Q1 | 36.78 Million AUD | -27.73% |
| 2015 FY | 30.74 Million AUD | -39.6% |
| 2014 FY | 50.9 Million AUD | 18.49% |
| 2014 Q2 | 39.51 Million AUD | 0.0% |
| 2014 Q1 | 39.51 Million AUD | -8.01% |
| 2014 Q3 | 50.9 Million AUD | 28.81% |
| 2014 Q4 | 50.9 Million AUD | 0.0% |
| 2013 FY | 42.95 Million AUD | -33.0% |
| 2013 Q4 | 42.95 Million AUD | 3.05% |
| 2013 Q3 | 41.68 Million AUD | -15.44% |
| 2013 Q2 | 49.3 Million AUD | 0.0% |
| 2013 Q1 | 49.3 Million AUD | -23.11% |
| 2012 FY | 64.12 Million AUD | -16.27% |
| 2012 Q4 | 64.12 Million AUD | 0.0% |
| 2011 Q4 | 76.57 Million AUD | 0.0% |
| 2011 FY | 76.57 Million AUD | 42.42% |
| 2010 Q4 | 53.76 Million AUD | 0.0% |
| 2010 FY | 53.76 Million AUD | -20.18% |
| 2009 Q4 | 67.36 Million AUD | 0.0% |
| 2009 FY | 67.36 Million AUD | -2.64% |
| 2008 FY | 69.18 Million AUD | -59.66% |
| 2008 Q4 | 69.18 Million AUD | 0.0% |
| 2007 Q4 | 171.52 Million AUD | 0.0% |
| 2007 FY | 171.52 Million AUD | -1.14% |
| 2006 FY | 173.49 Million AUD | 1.42% |
| 2006 Q4 | 173.49 Million AUD | 0.0% |
| 2005 FY | 171.07 Million AUD | 50.02% |
| 2005 Q4 | 171.07 Million AUD | 0.0% |
| 2004 Q4 | 114.03 Million AUD | 0.0% |
| 2004 FY | 114.03 Million AUD | 287.76% |
| 2003 Q4 | 29.4 Million AUD | 0.0% |
| 2003 FY | 29.4 Million AUD | 98.19% |
| 2002 Q4 | 14.83 Million AUD | 0.0% |
| 2002 FY | 14.83 Million AUD | -19.34% |
| 2001 FY | 18.39 Million AUD | -11.81% |
| 2001 Q4 | 18.39 Million AUD | 0.0% |
| 2000 Q4 | 20.85 Million AUD | 0.0% |
| 2000 FY | 20.85 Million AUD | 309.32% |
| 1999 Q4 | 5.09 Million AUD | 0.0% |
| 1999 FY | 5.09 Million AUD | 214.49% |
| 1998 Q4 | 1.62 Million AUD | 0.0% |
| 1998 FY | 1.62 Million AUD | -70.66% |
| 1997 FY | 5.52 Million AUD | -83.27% |
| 1997 Q4 | 5.52 Million AUD | 0.0% |
| 1996 FY | 33.01 Million AUD | -4.27% |
| 1995 FY | 34.48 Million AUD | 208.07% |
| 1994 FY | 11.19 Million AUD | -5.74% |
| 1993 FY | 11.87 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ContraFect Corporation | 20.67 Million USD | 64.605% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 184.00 USD | -3977785.87% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -166.512% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1366.681% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 81.159% |
| Kadimastem Ltd | 2.3 Million USD | -217.667% |
| Zenith Capital Corp. | 7410.00 USD | -98676.113% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -5019.401% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 75.614% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -9486.02% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -1815.162% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 94.379% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -10014.434% |
| Qrons Inc. | 420.00 USD | -1742592.857% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -32029.011% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2174.448% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -678.908% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1595.407% |
| Affymax, Inc. | 7.44 Million USD | 1.662% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 98.36% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -273.78% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -76.538% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -316753.247% |
| Biomind Labs Inc. | 73.81 Thousand USD | -9815.212% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 86.112% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -2701.36% |
| CytoDyn Inc. | 11.13 Million USD | 34.273% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 30.649% |
| IMV Inc. | 31.33 Million USD | 76.641% |
| Genus plc | 1.02 Billion USD | 99.289% |
| Halberd Corporation | 10.13 Thousand USD | -72146.669% |
| Helix BioMedix, Inc. | 3.02 Million USD | -141.954% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -1.379% |
| LadRx Corporation | 2.3 Million USD | -217.144% |
| Marizyme, Inc. | 22.01 Million USD | 66.753% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -40835.738% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 79.194% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -1774.987% |
| Q BioMed Inc. | 3.51 Million USD | -108.2% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1969.841% |
| Enzolytics Inc. | 361.7 Million USD | 97.976% |
| CSL Limited | 38.02 Billion USD | 99.981% |
| Skye Bioscience, Inc. | 11.94 Million USD | 38.701% |
| SQZ Biotechnologies Company | 107.18 Million USD | 93.171% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -120.926% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -438.837% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -2700.428% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1044.257% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 84.656% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1067.354% |
| NovAccess Global Inc. | 62.24 Thousand USD | -11658.305% |
| HST Global, Inc. | 1526.00 USD | -479540.236% |
| SYBLEU INC | 330.46 Thousand USD | -2114.832% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 94.304% |
| Alpha Cognition Inc. | 2.45 Million USD | -198.483% |
| AVAX Technologies, Inc. | 7.37 Million USD | 0.784% |
| Mesoblast Limited | 667.9 Million USD | 98.904% |
| MultiCell Technologies, Inc. | 126.22 USD | -5798751.212% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -411.114% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -964.649% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -849.765% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 98.419% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -181.166% |
| GB Sciences, Inc. | 103.44 Thousand USD | -6975.762% |
| argenx SE | 4.54 Billion USD | 99.839% |
| Resverlogix Corp. | 8.11 Million USD | 9.805% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -289.765% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 73.807% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -405.183% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 18.212% |
| ONE Bio Corp. | 70.08 Million USD | 89.557% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.784% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -688.752% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -640.846% |
| Agentix Corp. | 261.39 Thousand USD | -2700.128% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | 49.731% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -12719.753% |
| Cell Source, Inc. | 195.17 Thousand USD | -3650.204% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1423.089% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1969.841% |
| Itoco Inc. | 1.4 Million USD | -422.781% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -7551.62% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -6805.009% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -1798.797% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1225.674% |
| Rebus Holdings, Inc. | 5000.00 USD | -146286.2% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1687.718% |
| Mobile Lads Corp. | 52.00 USD | -14075496.154% |
| International Stem Cell Corporation | 5.39 Million USD | -35.794% |
| Bioxytran, Inc. | 137.63 Thousand USD | -5217.797% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 51.211% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 55.852% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -9164.949% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -746.479% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 2.63% |
| Neutra Corp. | 2851.00 USD | -256627.815% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 77.414% |
| PureTech Health plc | 693.97 Million USD | 98.945% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 9.314% |
| IXICO plc | 15.84 Million USD | 53.804% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 11.624% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 92.916% |
| CSL Limited | 38.02 Billion USD | 99.981% |
| Cellectis S.A. | 333.99 Million USD | 97.809% |